[S-methyl-11C]-L-methionine positron emission tomography/computed tomography imaging parameters to evaluate early response for esophageal cancer with neoadjuvant carbon ion radiotherapy. 2022

Kazuo Narushima, and Ryuichi Nishii, and Shinichi Okazumi, and Hideaki Shimada, and Yasunori Akutsu, and Takamasa Maeda, and Shigeo Yasuda, and Shigeru Yamada, and Kiyohiko Shuto, and Kentaro Tamura, and Kana Yamazaki, and Makoto Shinoto, and Hitoshi Ishikawa, and Mikito Mori, and Hisahiro Matsubara
Department of Surgery, Secomedic Hospital, Chiba, Japan.

This study aimed to evaluate the uptake of the clinical effectiveness of [S-methyl-11C]-L-methionine positron emission tomography/computed tomography (MET PET/CT) in patients with esophageal cancer and to investigate MET PET/CT imaging parameters to assess early response for esophageal cancer with neoadjuvant carbon ion radiotherapy (CIRT). MET PET/CT scans were performed in nineteen patients before and 3 weeks after completion of CIRT. After Surgery, the effect of neoadjuvant CIRT was investigated by examining the relationship between each parameter of MET uptake and the histological assessment (grade and tumor residual ratio). Four parameters of MET uptake were the maximum and minimum standardized uptake values of pre and post CIRT (pre-SUVmax, pre-SUVmean, post-SUVmax, and post-SUVmean). MET PET/CT imaging of esophageal cancer was clearly demonstrated. The post-SUVmax was the most suitable parameter. When the cutoff value was set as post-SUVmax = 6.21, the sensitivity, the specificity, and the accuracy of Grades 3 were 100.0%, 63.6%, and 78.9%, respectively. And there was a positive relationship between the tumor residual ratio and post-SUVmax (R2 = 0.38, p < 0.005). MET PET/CT is clinically useful for the assessment of early response to neoadjuvant CIRT in esophageal cancer. Particularly, post-SUVmax is considered a promising PET imaging parameter.

UI MeSH Term Description Entries
D008715 Methionine A sulfur-containing essential L-amino acid that is important in many body functions. L-Methionine,Liquimeth,Methionine, L-Isomer,Pedameth,L-Isomer Methionine,Methionine, L Isomer
D004938 Esophageal Neoplasms Tumors or cancer of the ESOPHAGUS. Cancer of Esophagus,Esophageal Cancer,Cancer of the Esophagus,Esophagus Cancer,Esophagus Neoplasm,Neoplasms, Esophageal,Cancer, Esophageal,Cancer, Esophagus,Cancers, Esophageal,Cancers, Esophagus,Esophageal Cancers,Esophageal Neoplasm,Esophagus Cancers,Esophagus Neoplasms,Neoplasm, Esophageal,Neoplasm, Esophagus,Neoplasms, Esophagus
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000072078 Positron Emission Tomography Computed Tomography An imaging technique that combines a POSITRON-EMISSION TOMOGRAPHY (PET) scanner and a CT X RAY scanner. This establishes a precise anatomic localization in the same session. CT PET,CT PET Scan,PET CT Scan,PET-CT,PET-CT Scan,Positron Emission Tomography-Computed Tomography,CT PET Scans,CT Scan, PET,CT Scans, PET,PET CT Scans,PET Scan, CT,PET Scans, CT,PET-CT Scans,Scan, CT PET,Scan, PET CT,Scan, PET-CT,Scans, CT PET,Scans, PET CT,Scans, PET-CT
D049268 Positron-Emission Tomography An imaging technique using compounds labelled with short-lived positron-emitting radionuclides (such as carbon-11, nitrogen-13, oxygen-15 and fluorine-18) to measure cell metabolism. It has been useful in study of soft tissues such as CANCER; CARDIOVASCULAR SYSTEM; and brain. SINGLE-PHOTON EMISSION-COMPUTED TOMOGRAPHY is closely related to positron emission tomography, but uses isotopes with longer half-lives and resolution is lower. PET Imaging,PET Scan,Positron-Emission Tomography Imaging,Tomography, Positron-Emission,Imaging, PET,Imaging, Positron-Emission Tomography,PET Imagings,PET Scans,Positron Emission Tomography,Positron Emission Tomography Imaging,Positron-Emission Tomography Imagings,Scan, PET,Tomography Imaging, Positron-Emission,Tomography, Positron Emission
D019275 Radiopharmaceuticals Compounds that are used in medicine as sources of radiation for radiotherapy and for diagnostic purposes. They have numerous uses in research and industry. (Martindale, The Extra Pharmacopoeia, 30th ed, p1161) Radiopharmaceutical
D019788 Fluorodeoxyglucose F18 The compound is given by intravenous injection to do POSITRON-EMISSION TOMOGRAPHY for the assessment of cerebral and myocardial glucose metabolism in various physiological or pathological states including stroke and myocardial ischemia. It is also employed for the detection of malignant tumors including those of the brain, liver, and thyroid gland. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1162) 18F Fluorodeoxyglucose,18FDG,2-Fluoro-2-deoxy-D-glucose,2-Fluoro-2-deoxyglucose,Fludeoxyglucose F 18,18F-FDG,Fluorine-18-fluorodeoxyglucose,Fluorodeoxyglucose F 18,2 Fluoro 2 deoxy D glucose,2 Fluoro 2 deoxyglucose,F 18, Fludeoxyglucose,F 18, Fluorodeoxyglucose,F18, Fluorodeoxyglucose,Fluorine 18 fluorodeoxyglucose,Fluorodeoxyglucose, 18F
D020360 Neoadjuvant Therapy Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, IMMUNOTHERAPY, HYPERTHERMIA, INDUCED etc.) that is given before the main therapy. Neoadjuvant Chemoradiation,Neoadjuvant Chemoradiation Therapy,Neoadjuvant Chemoradiation Treatment,Neoadjuvant Chemoradiotherapy,Neoadjuvant Chemotherapy,Neoadjuvant Chemotherapy Treatment,Neoadjuvant Radiation,Neoadjuvant Radiation Therapy,Neoadjuvant Radiation Treatment,Neoadjuvant Radiotherapy,Neoadjuvant Systemic Therapy,Neoadjuvant Systemic Treatment,Neoadjuvant Treatment,Chemoradiation Therapy, Neoadjuvant,Chemoradiation Treatment, Neoadjuvant,Chemoradiation, Neoadjuvant,Chemoradiotherapy, Neoadjuvant,Chemotherapy Treatment, Neoadjuvant,Chemotherapy, Neoadjuvant,Neoadjuvant Chemoradiation Therapies,Neoadjuvant Chemoradiation Treatments,Neoadjuvant Chemoradiations,Neoadjuvant Chemoradiotherapies,Neoadjuvant Chemotherapies,Neoadjuvant Chemotherapy Treatments,Neoadjuvant Radiation Therapies,Neoadjuvant Radiation Treatments,Neoadjuvant Radiations,Neoadjuvant Radiotherapies,Neoadjuvant Systemic Therapies,Neoadjuvant Systemic Treatments,Neoadjuvant Therapies,Neoadjuvant Treatments,Radiation Therapy, Neoadjuvant,Radiation Treatment, Neoadjuvant,Radiation, Neoadjuvant,Radiotherapy, Neoadjuvant,Systemic Therapy, Neoadjuvant,Systemic Treatment, Neoadjuvant,Therapy, Neoadjuvant,Therapy, Neoadjuvant Chemoradiation,Therapy, Neoadjuvant Radiation,Therapy, Neoadjuvant Systemic,Treatment, Neoadjuvant,Treatment, Neoadjuvant Chemoradiation,Treatment, Neoadjuvant Chemotherapy,Treatment, Neoadjuvant Radiation,Treatment, Neoadjuvant Systemic
D063193 Heavy Ion Radiotherapy The use of a heavy ion particle beam for radiotherapy, such as the HEAVY IONS of CARBON. Carbon Ion Radiation Therapy,Carbon Ion Radiotherapy,Carbon Ion Therapy,Heavy Ion Radiation Therapy,Heavy Ion Therapy,Carbon Ion Therapies,Heavy Ion Radiotherapies,Heavy Ion Therapies,Radiotherapies, Heavy Ion,Radiotherapy, Carbon Ion,Radiotherapy, Heavy Ion,Therapies, Carbon Ion,Therapies, Heavy Ion,Therapy, Carbon Ion,Therapy, Heavy Ion

Related Publications

Kazuo Narushima, and Ryuichi Nishii, and Shinichi Okazumi, and Hideaki Shimada, and Yasunori Akutsu, and Takamasa Maeda, and Shigeo Yasuda, and Shigeru Yamada, and Kiyohiko Shuto, and Kentaro Tamura, and Kana Yamazaki, and Makoto Shinoto, and Hitoshi Ishikawa, and Mikito Mori, and Hisahiro Matsubara
April 2024, Annals of nuclear medicine,
Kazuo Narushima, and Ryuichi Nishii, and Shinichi Okazumi, and Hideaki Shimada, and Yasunori Akutsu, and Takamasa Maeda, and Shigeo Yasuda, and Shigeru Yamada, and Kiyohiko Shuto, and Kentaro Tamura, and Kana Yamazaki, and Makoto Shinoto, and Hitoshi Ishikawa, and Mikito Mori, and Hisahiro Matsubara
January 2019, Methods in molecular biology (Clifton, N.J.),
Kazuo Narushima, and Ryuichi Nishii, and Shinichi Okazumi, and Hideaki Shimada, and Yasunori Akutsu, and Takamasa Maeda, and Shigeo Yasuda, and Shigeru Yamada, and Kiyohiko Shuto, and Kentaro Tamura, and Kana Yamazaki, and Makoto Shinoto, and Hitoshi Ishikawa, and Mikito Mori, and Hisahiro Matsubara
January 1987, Neuroradiology,
Kazuo Narushima, and Ryuichi Nishii, and Shinichi Okazumi, and Hideaki Shimada, and Yasunori Akutsu, and Takamasa Maeda, and Shigeo Yasuda, and Shigeru Yamada, and Kiyohiko Shuto, and Kentaro Tamura, and Kana Yamazaki, and Makoto Shinoto, and Hitoshi Ishikawa, and Mikito Mori, and Hisahiro Matsubara
July 1979, Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
Kazuo Narushima, and Ryuichi Nishii, and Shinichi Okazumi, and Hideaki Shimada, and Yasunori Akutsu, and Takamasa Maeda, and Shigeo Yasuda, and Shigeru Yamada, and Kiyohiko Shuto, and Kentaro Tamura, and Kana Yamazaki, and Makoto Shinoto, and Hitoshi Ishikawa, and Mikito Mori, and Hisahiro Matsubara
September 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,
Kazuo Narushima, and Ryuichi Nishii, and Shinichi Okazumi, and Hideaki Shimada, and Yasunori Akutsu, and Takamasa Maeda, and Shigeo Yasuda, and Shigeru Yamada, and Kiyohiko Shuto, and Kentaro Tamura, and Kana Yamazaki, and Makoto Shinoto, and Hitoshi Ishikawa, and Mikito Mori, and Hisahiro Matsubara
September 2005, International journal of radiation oncology, biology, physics,
Kazuo Narushima, and Ryuichi Nishii, and Shinichi Okazumi, and Hideaki Shimada, and Yasunori Akutsu, and Takamasa Maeda, and Shigeo Yasuda, and Shigeru Yamada, and Kiyohiko Shuto, and Kentaro Tamura, and Kana Yamazaki, and Makoto Shinoto, and Hitoshi Ishikawa, and Mikito Mori, and Hisahiro Matsubara
June 2007, Nan fang yi ke da xue xue bao = Journal of Southern Medical University,
Kazuo Narushima, and Ryuichi Nishii, and Shinichi Okazumi, and Hideaki Shimada, and Yasunori Akutsu, and Takamasa Maeda, and Shigeo Yasuda, and Shigeru Yamada, and Kiyohiko Shuto, and Kentaro Tamura, and Kana Yamazaki, and Makoto Shinoto, and Hitoshi Ishikawa, and Mikito Mori, and Hisahiro Matsubara
March 1996, Proceedings of the National Academy of Sciences of the United States of America,
Kazuo Narushima, and Ryuichi Nishii, and Shinichi Okazumi, and Hideaki Shimada, and Yasunori Akutsu, and Takamasa Maeda, and Shigeo Yasuda, and Shigeru Yamada, and Kiyohiko Shuto, and Kentaro Tamura, and Kana Yamazaki, and Makoto Shinoto, and Hitoshi Ishikawa, and Mikito Mori, and Hisahiro Matsubara
January 1985, AJNR. American journal of neuroradiology,
Kazuo Narushima, and Ryuichi Nishii, and Shinichi Okazumi, and Hideaki Shimada, and Yasunori Akutsu, and Takamasa Maeda, and Shigeo Yasuda, and Shigeru Yamada, and Kiyohiko Shuto, and Kentaro Tamura, and Kana Yamazaki, and Makoto Shinoto, and Hitoshi Ishikawa, and Mikito Mori, and Hisahiro Matsubara
January 1985, Journal of computer assisted tomography,
Copied contents to your clipboard!